// App-Quantinova.ai

395 : A first-in-human study of FS118, a tetravalent bispecific antibody targeting LAG-3 and PD-L1, in patients with advanced cancer and resistance to PD-(L)1 therapy

Researchers

Presenter

  • Timothy Yap

Principal Investigators

  • Deborah Wong

  • Siwen Hu-Lieskovan

  • Kyriakos Papadopoulos

  • Michelle Morrow

  • Urszula Grabowska

  • Daniel Gliddon

  • Josefin-Beate Holz

  • Patricia Lo Russo

Medical Centers

  • UCLA and the Jonsson Comprehensive Cancer Center, Los Angeles, CA

  • Huntsman Cancer Institute and Hospital, Salt Lake City, UT, USA

  • START, San Antonio, Texas, USA

  • F-star Therapeutics Ltd, Cambridge, UK

  • Yale Cancer Center, New Haven, CT

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • FS118

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Pharmacodynamics

  • Dose Escalation

  • First-In-Human

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved